Colleen Moretti


Analysis: Feasible to explore RT plus next-gen hormonal therapy in phase 3 high-risk local prostate cancer trials

June 09, 2022

Combining radiotherapy with next-generation hormonal therapy is a feasible approach to explore in phase 3 trials enrolling patients with high-risk localized or locally advanced prostate cancer, according to an analysis of the phase 3 ATLAS trial.